{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:24Z","timestamp":1786987824057,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ebiom.2026.106204","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:15:28Z","timestamp":1773130528000},"page":"106204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-8895","authenticated-orcid":false,"given":"Nicole","family":"Shaver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Colijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon Darko","family":"Asamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Piggott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Kagina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-2957","authenticated-orcid":false,"given":"Dawn M.E.","family":"Bowdish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-5531","authenticated-orcid":false,"given":"Julian","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106204_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14760584.2019.1559063","article-title":"Current perspectives in assessing humoral immunity after measles vaccination","volume":"18","author":"Haralambieva","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ebiom.2026.106204_bib2","series-title":"Phases of Clinical Trials","year":"2023"},{"key":"10.1016\/j.ebiom.2026.106204_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.06.041","article-title":"COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies","volume":"42","author":"Bhella","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/vaccines13010019","article-title":"Immunobridging trials: an important tool to protect vulnerable and immunocompromised patients against evolving pathogens","volume":"13","author":"Cruz","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.ebiom.2026.106204_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(23)00572-8","article-title":"Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1\/2, double-masked, dose-finding, active-controlled, randomised clinical trial","volume":"24","author":"Wassil","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106204_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-Valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106204_bib7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2017.02.066","article-title":"Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: a phase 3, randomized noninferiority study","volume":"35","author":"Treanor","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/1471-2334-13-343","article-title":"Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged \u226518 years","volume":"13","author":"Kieninger","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106204_bib9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.vaccine.2014.01.022","article-title":"Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged \u226518 years: a phase III, randomized trial","volume":"32","author":"Tinoco","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib10","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials","volume":"12","author":"Baisley","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ebiom.2026.106204_bib11","series-title":"Primary End-Points for Prophylactic HPV Vaccine Trials","year":"2014"},{"key":"10.1016\/j.ebiom.2026.106204_bib12","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib13","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1016\/j.vaccine.2023.09.012","article-title":"Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness","volume":"41","author":"Shaver","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib14","series-title":"Living Systematic Review on Immunological Outcomes of Vaccine Effectiveness on Variants of Concern Dashboard \u2013 The Nab VEVOC Dashboard","author":"Asamoah","year":"2023"},{"key":"10.1016\/j.ebiom.2026.106204_bib15","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1038\/s41467-020-18450-4","article-title":"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2026.106204_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/eri.11.51","article-title":"Serologic assays for influenza surveillance, diagnosis and vaccine evaluation","volume":"9","author":"Katz","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ebiom.2026.106204_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13088","article-title":"Advances in neutralization assays for SARS-CoV-2","volume":"94","author":"Lu","year":"2021","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142362","article-title":"A simple protein-based surrogate neutralization assay for SARS-CoV-2","volume":"5","author":"Abe","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2026.106204_bib19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.pathol.2020.09.006","article-title":"Laboratory biosafety measures involving SARS-CoV-2 and the classification as a risk group 3 biological agent","volume":"52","author":"Kaufer","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.ebiom.2026.106204_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102234","article-title":"The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design","volume":"78","author":"Britto","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1156758","article-title":"Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection","volume":"14","author":"Escudero-P\u00e9rez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166059","article-title":"Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development","volume":"14","author":"Paramithiotis","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4049\/immunohorizons.2300095","article-title":"Improving reliability of immunological assays by defining minimal criteria for cell fitness","volume":"8","author":"Ivison","year":"2024","journal-title":"Immunohorizons"},{"key":"10.1016\/j.ebiom.2026.106204_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/vim.2020.0313","article-title":"Review of clinical performance of serology based commercial diagnostic assays for detection of severe acute respiratory syndrome Coronavirus 2 antibodies","volume":"35","author":"Deshpande","year":"2022","journal-title":"Viral Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4236\/oji.2020.102003","article-title":"Analysis of commercial assays for the detection of SARS-CoV-2 antibodies or antigens","volume":"10","author":"Gonz\u00e1lez","year":"2020","journal-title":"Open J Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib28","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.vaccine.2014.01.060","article-title":"Methodological quality of systematic reviews on influenza vaccination","volume":"32","author":"Remschmidt","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12879-015-1154-y","article-title":"Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review","volume":"15","author":"Remschmidt","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106204_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1741-7015-11-153","article-title":"Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis","volume":"11","author":"Tricco","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.ebiom.2026.106204_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/vaccines10010082","article-title":"Effectiveness and efficacy of vaccine on mutated SARS-CoV-2 virus and post vaccination surveillance: a narrative review","volume":"10","author":"Hafiz","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ebiom.2026.106204_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib33","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1016\/j.vaccine.2021.05.099","article-title":"Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization","volume":"39","author":"Patel","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106204_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/irv.12411","article-title":"CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES -I statement): an extension of the STROBE statement","volume":"11","author":"Horby","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.ebiom.2026.106204_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/irv.12870","article-title":"ROSES-S: statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2","volume":"15","year":"2021","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.ebiom.2026.106204_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13283","article-title":"Adherence of SARS-CoV-2 seroepidemiologic studies to the ROSES-S reporting guideline during the COVID-19 pandemic","volume":"18","author":"Cheng","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.ebiom.2026.106204_bib37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3201\/eid2803.211885","article-title":"Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications","volume":"28","author":"Stone","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106204_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(23)00964-9","article-title":"Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and response","volume":"402","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2026.106204_bib39","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.3390\/vaccines10122000","article-title":"Serology assays used in SARS-CoV-2 seroprevalence surveys worldwide: a systematic review and meta-analysis of assay features, testing algorithms, and performance","volume":"10","author":"Ma","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.ebiom.2026.106204_bib40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jrsm.1620","article-title":"SeroTracker-RoB: a decision rule-based algorithm for reproducible risk of bias assessment of seroprevalence studies","volume":"14","author":"Bobrovitz","year":"2023","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ebiom.2026.106204_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2026.106204_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12874-023-02110-4","article-title":"Exploring trial publication and research waste in COVID-19 randomised trials of hydroxychloroquine, corticosteroids, and vitamin D: a meta-epidemiological cohort study","volume":"24","author":"Fincham","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ebiom.2026.106204_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061862","article-title":"Extent and nature of duplication in PROSPERO using COVID-19-related registrations: a retrospective investigation and survey","volume":"12","author":"Beresford","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ebiom.2026.106204_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110484","article-title":"Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination","volume":"27","author":"Cuperlovic-Culf","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ebiom.2026.106204_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41541-024-00949-2","article-title":"WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58","volume":"9","author":"Kemp","year":"2024","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.ebiom.2026.106204_bib47","series-title":"1st WHO International Reference Panel for HIV-1 p24 Antigen","year":"2024"},{"key":"10.1016\/j.ebiom.2026.106204_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011403","article-title":"The HPV serology laboratory leads an initiative to standardize and harmonize human papillomavirus serology assays","volume":"19","author":"Park","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ebiom.2026.106204_bib50","series-title":"First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin (human)","year":"2023"},{"key":"10.1016\/j.ebiom.2026.106204_bib51","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2666-5247(23)00258-6","article-title":"The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays","volume":"5","author":"Hempel","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ebiom.2026.106204_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00193-22","article-title":"The serological sciences network (SeroNet) for COVID-19: depth and breadth of serology assays and plans for assay harmonization","volume":"7","author":"Karger","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.ebiom.2026.106204_bib53","series-title":"1st International Reference Panel for antibodies to SARS-CoV-2 variants of concern 22\/270","year":"2020"},{"key":"10.1016\/j.ebiom.2026.106204_bib54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11673-020-10019-6","article-title":"Learning lessons from COVID-19 requires recognizing moral failures","volume":"17","author":"Smith","year":"2020","journal-title":"J Bioeth Inq"},{"key":"10.1016\/j.ebiom.2026.106204_bib55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14745\/ccdr.v44i05a01","article-title":"Fifteen years post-SARS: key milestones in Canada's public health emergency response","volume":"44","author":"Tam","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.ebiom.2026.106204_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3904\/kjim.2018.031","article-title":"Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea","volume":"33","author":"Oh","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.ebiom.2026.106204_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/bio.2020.29075.drc","article-title":"Expanding the BBMRI-ERIC directory into a global catalogue of COVID-19-Ready collections: a joint initiative of BBMRI-ERIC and ISBER","volume":"18","author":"Catchpoole","year":"2020","journal-title":"Biopreserv Biobank"},{"key":"10.1016\/j.ebiom.2026.106204_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10270","article-title":"Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens","volume":"8","author":"Cholette","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ebiom.2026.106204_bib61","first-page":"75","article-title":"No time for complacency: the CoVaRR-Net Biobank is an essential element of laboratory preparedness for infectious disease outbreaks","volume":"8","author":"Saginur","year":"2023","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"10.1016\/j.ebiom.2026.106204_bib62","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/ije\/dyq139","article-title":"Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies","volume":"39","author":"Fortier","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ebiom.2026.106204_bib63","first-page":"103","article-title":"Maelstrom research guidelines for rigorous retrospective data harmonization","volume":"46","author":"Fortier","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ebiom.2026.106204_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-7622-10-12","article-title":"Data harmonization and federated analysis of population-based studies: the BioSHaRE project","volume":"10","author":"Doiron","year":"2013","journal-title":"Emerg Themes Epidemiol"},{"key":"10.1016\/j.ebiom.2026.106204_bib65","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41431-020-0634-8","article-title":"BBMRI-ERIC\u2019s contributions to research and knowledge exchange on COVID-19","volume":"28","author":"Holub","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ebiom.2026.106204_bib68","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1373\/clinchem.2011.168641","article-title":"Proficiency testing\/external quality assessment: current challenges and future directions","volume":"57","author":"Miller","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.ebiom.2026.106204_bib69","author":"Brooker"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:59:49Z","timestamp":1783972789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":61,"alternative-id":["S2352396426000861"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106204","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106204"}}